Repurposing of macrolide antibiotic clarithromycin for the prevention of lung and breast cancer
Ended Awarded Last action
- Contract number
- 75N91019F00131
- Awardee
-
The Univeristy Of Texas M.d. Anderson Cancer Center UEI S3GMKS8ELA16 Part of University Of Texas System
- Awarding agency
-
National Cancer Institute
National Institutes of Health, Department of Health and Human Services
- Obligated
- $912,585
Award facts
- Opportunity
-
- PREVENT Cancer Preclinical Drug Development Program: Preclinical Efficacy and Intermediate Biomarker Endpoints, Preclinical Services for Biopharmaceutical Product Development and Manufacturing, and Toxicology and Pharmacology Testing Pre-Solicitation · N01CN7701918 · Posted Apr 19, 2018
- PREVENT Cancer Preclinical Drug Development Program Award Notice · Posted May 7, 2018
- Contract value 100% obligated
- $912,585.00 Current and potential, with all options
- Completion date 100% complete
- Current and potential, with all options
- NAICS code
- 541714 Research and Development in Biotechnology (except Nanobiotechnology)
- Set-aside
- No set-aside
- Competition
- Full and Open Competition · 2 offers Multiple Award, Fair Opportunity
- Pricing
- Firm Fixed Price
- Place of performance
- Houston, TX 77030, USA
- Legislative mandates
-
- Walsh-Healey Public Contracts Act FAR subpart 22.6
- Service Contract Inventory FAR subpart 4.17
Award details come from SAM.gov/FPDS.
Transactions
| Action | Obligated | Date |
|---|---|---|
| Other Administrative Action | -$6,396 | |
| Supplemental Agreement for work within scope | $0 | |
| Supplemental Agreement for work within scope | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Other Administrative Action | $0 | |
| Original award | $918,981 |
About this award
The University of Texas M.D. Anderson Cancer Center has been awarded a $912,585 firm fixed price delivery order against the PREVENT Preclinical Drug Development Program multiple award IDIQ vehicle to repurpose the macrolide antibiotic clarithromycin for the prevention of lung and breast cancer. The work will be performed under the PREVENT Program's PRECLINICAL EFFICACY & INTERMEDIATE BIOMARKERS major program code, with the goal of assessing clarithromycin's preclinical efficacy and developing intermediate biomarkers. Funding is provided by the National Cancer Institute, part of the National Institutes of Health within the Department of Health and Human Services. Work will be conducted at the prime contractor's location in Houston, Texas through September 2023.
Quick answers
Who was awarded contract 75N91019F00131?
75N91019F00131 was awarded to The Univeristy Of Texas M.d. Anderson Cancer Center by National Cancer Institute (National Institutes of Health) on September 15, 2019.
How much is contract 75N91019F00131 worth?
The government has obligated $912,585 on 75N91019F00131.
Is contract 75N91019F00131 an order under another contract?
Yes. 75N91019F00131 is a delivery order under 75N91019D00021, an indefinite delivery contract, on PREVENT Preclinical Drug Development Program (PREVENT).
Was contract 75N91019F00131 competed?
The extent of competition for 75N91019F00131 was full and open competition. The government received 2 offers.
On GovTribe
See this award's full record
- Every transaction and funding action
- The awardee's other awards and teaming partners
- Similar awards and recompete opportunities
- Ask GovTribe AI about this award